This company has been marked as potentially delisted and may not be actively trading. Stellar Biotechnologies (SBOT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SBOT vs. AMRN, AVTE, ACTU, LXRX, DSGN, TNXP, OMER, YMAB, ADCT, and SCPHShould you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Amarin (AMRN), Aerovate Therapeutics (AVTE), Actuate Therapeutics (ACTU), Lexicon Pharmaceuticals (LXRX), Design Therapeutics (DSGN), Tonix Pharmaceuticals (TNXP), Omeros (OMER), Y-mAbs Therapeutics (YMAB), ADC Therapeutics (ADCT), and scPharmaceuticals (SCPH). These companies are all part of the "medical" sector. Stellar Biotechnologies vs. Amarin Aerovate Therapeutics Actuate Therapeutics Lexicon Pharmaceuticals Design Therapeutics Tonix Pharmaceuticals Omeros Y-mAbs Therapeutics ADC Therapeutics scPharmaceuticals Amarin (NASDAQ:AMRN) and Stellar Biotechnologies (NASDAQ:SBOT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment, community ranking and earnings. Is AMRN or SBOT more profitable? Amarin has a net margin of -16.33% compared to Stellar Biotechnologies' net margin of -1,782.64%. Amarin's return on equity of -7.22% beat Stellar Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Amarin-16.33% -7.22% -4.96% Stellar Biotechnologies -1,782.64%-51.12%-48.37% Does the MarketBeat Community favor AMRN or SBOT? Amarin received 610 more outperform votes than Stellar Biotechnologies when rated by MarketBeat users. Likewise, 73.20% of users gave Amarin an outperform vote while only 66.48% of users gave Stellar Biotechnologies an outperform vote. CompanyUnderperformOutperformAmarinOutperform Votes84473.20% Underperform Votes30926.80% Stellar BiotechnologiesOutperform Votes23466.48% Underperform Votes11833.52% Does the media favor AMRN or SBOT? In the previous week, Amarin had 1 more articles in the media than Stellar Biotechnologies. MarketBeat recorded 1 mentions for Amarin and 0 mentions for Stellar Biotechnologies. Amarin's average media sentiment score of 0.75 beat Stellar Biotechnologies' score of 0.00 indicating that Amarin is being referred to more favorably in the media. Company Overall Sentiment Amarin Positive Stellar Biotechnologies Neutral Do insiders and institutionals hold more shares of AMRN or SBOT? 22.3% of Amarin shares are held by institutional investors. Comparatively, 1.7% of Stellar Biotechnologies shares are held by institutional investors. 3.3% of Amarin shares are held by insiders. Comparatively, 7.8% of Stellar Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has higher earnings and valuation, AMRN or SBOT? Stellar Biotechnologies has lower revenue, but higher earnings than Amarin. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$214.11M1.07-$59.11M-$3.64-3.05Stellar Biotechnologies$210K295.18-$5.03M-$1.76-6.61 Do analysts prefer AMRN or SBOT? Amarin presently has a consensus price target of $7.00, suggesting a potential downside of 36.99%. Given Amarin's stronger consensus rating and higher probable upside, equities analysts plainly believe Amarin is more favorable than Stellar Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Stellar Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAmarin beats Stellar Biotechnologies on 12 of the 17 factors compared between the two stocks. Get Stellar Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBOT vs. The Competition Export to ExcelMetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.99M$6.47B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E Ratio-6.618.4026.7219.60Price / Sales295.18258.84395.56117.96Price / CashN/A65.8538.3234.62Price / Book5.496.416.764.50Net Income-$5.03M$143.73M$3.23B$248.40M Stellar Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBOTStellar BiotechnologiesN/A$11.63+21.1%N/A+228.8%$61.99M$210,000.00-6.6125Gap UpHigh Trading VolumeAMRNAmarin0.3678 of 5 stars$10.90+3.0%$7.00-35.8%-37.0%$219.10M$214.11M-121.11360AVTEAerovate Therapeutics1.4784 of 5 stars$7.35-0.7%$78.75+972.2%-98.8%$212.90MN/A-2.4620Positive NewsHigh Trading VolumeACTUActuate TherapeuticsN/A$10.26-2.7%$20.50+99.8%N/A$206.06MN/A0.0010News CoverageLXRXLexicon Pharmaceuticals3.3432 of 5 stars$0.56+3.8%$3.67+559.7%-60.5%$200.92M$31.08M-0.74140Gap DownDSGNDesign Therapeutics0.5572 of 5 stars$3.53+0.6%$4.00+13.3%-7.0%$200.40MN/A-4.1540Gap DownTNXPTonix Pharmaceuticals3.345 of 5 stars$26.60-5.0%$585.00+2,099.2%-95.7%$194.85M$10.04M-0.0150News CoverageAnalyst UpgradeHigh Trading VolumeOMEROmeros3.9606 of 5 stars$3.32+3.4%$22.50+577.7%-5.8%$193.58MN/A-1.44210Analyst RevisionGap DownHigh Trading VolumeYMABY-mAbs Therapeutics3.4337 of 5 stars$4.17+1.7%$16.60+298.1%-67.9%$188.83M$87.69M-7.72150Analyst RevisionGap DownADCTADC Therapeutics2.7121 of 5 stars$2.34+23.8%$7.75+231.2%-39.8%$187.45M$70.84M-0.98310Gap DownHigh Trading VolumeSCPHscPharmaceuticals4.0785 of 5 stars$3.52+9.3%$14.00+297.7%-0.8%$185.83M$41.98M-1.8530Gap DownHigh Trading Volume Related Companies and Tools Related Companies AMRN Competitors AVTE Competitors ACTU Competitors LXRX Competitors DSGN Competitors TNXP Competitors OMER Competitors YMAB Competitors ADCT Competitors SCPH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBOT) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stellar Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SBOT Stock Free SBOT Stock Alerts